NAGLAA MAKRAM FARAG

Prof. Dr. NAGLAA MAKRAM FARAG


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2019 in Clinical and Experimental Gastroenterology
Verified
Journal Article
Open access
PDF file
LALamia H Ali
Lamia H Ali
AHAliaa Monir Higazi
Aliaa Monir Higazi
HMHend M Moness
Hend M Moness
NFNAGLAA MAKRAM FARAG
NAGLAA MAKRAM FARAG
ZSZienab M Saad
Zienab M Saad
HHHaitham Abdl Hamid
Haitham Abdl Hamid
Background: Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide. It has been widely established that the early detection of HCC enables more treatment options with improvements in prognosis and survival. Objectives: The aim of this study was to assess the diagnostic accuracy of both circulating miR-215 and squamous cell carcinoma antigen-IgM (SCCA-IgM) as serum biomarkers for HCC by examining their diagnostic sensitivity, specificity, accuracy, and predictive values in hepatitis C virus (HCV)-induced HCC patients. Subjects and methods: This study included 60 patients with HCV-related HCC. In addition, 60 patients with HCV-related liver cirrhosis (LC) and 60 apparently healthy subjects were involved, and served as diseased and healthy control groups, respectively. The relative expression levels of miR-215 were detected using quantitative real-time PCR. SCCA-IgM levels in serum were measured by enzyme immunoassay. We used receiver operating characteristic (ROC) curve to calculate the diagnostic accuracy against alpha-fetoprotein (AFP). Results: Relative miR-215 expression levels increased the most in HCC patients compared to that in healthy or diseased controls (P<0.001). Serum concentration of SCCA-IgM was significantly higher in HCC group than that in the two control groups. We performed multivariate analysis using AFP level, focal lesion size, and portal vein thrombosis as independent variables. ROC curves showed that the optimum diagnostic miR-215 cutoff value for identifying HCC patients from cirrhotic ones was 417 (sensitivity, 97%; specificity, 91%) and for SCCA-IgM was 95 AU/mL (sensitivity, 92%; specificity, 98%). Moreover, the superiority of both miR-215 and SCCA-IgM to AFP is obvious in our study and this superiority is more evident in distinguishing HCC with AFP levels Conclusion: Cell-free miR-215 and serum SCCA-IgM could be used for early diagnosis of HCC either each one as a single marker or with AFP complement measurement.

30 August 2023 in Italian Journal of Pediatrics
Verified
Journal Article
Open access
PDF file
NFNAGLAA MAKRAM FARAG
NAGLAA MAKRAM FARAG
MMMahmoud Mousa
Mahmoud Mousa
EAEman Abouahmad
Eman Abouahmad
AIAhlam Ismeil
Ahlam Ismeil
Background: Anaemia is a common presenting feature among patients with chronic kidney disease (CKD) and associated with poor clinical outcomes. We evaluated the diagnostic validity of growth differentiation factor-15 (GDF-15) and hepcidin as it is not clear if they are useful as a biomarkers of anaemia among non-dialysis CKD egyptian patients. Method: An analytical cross-sectional study was conducted among non-dialysis CKD patients (n = 60) and apparently healthy controls (n = 28) at Minia University maternity & children Hospital. Serum levels of GDF-15 and hepcidin were determined. Predictive logistic regression models were built and post estimation receiver operator characteristics were determined to evaluate diagnostic validity of hepcidin and GDF-15 for iron deficiency anaemia. Results: Hepcidin and GDF-15 are significantly higher in cases than control p value (0.047 < 0.0001) respectively. The predictive value of diagnosing anaemia among CKD patients using hepcidin and GDF-15 was 72.0%, 70.0%. There was a weak negative correlation between hepcidin levels and glomerular filtration rate GFR (r = -.175, p = 0.105) in CKD patients, and significant correlation between serum GDF-15 and haemoglobin (r = -0.897, p < 0.0001), ferritin (r = 0.489, P < 0.000), Iron (r = -0.314, P = 0.002), CRP (r = 0.409, P < 0.0001). Conclusion: Hepcidin and GDF-15 is a potential biomarker for predicting anaemia connected with inflammation among CKD Egyptian patients.

26 August 2021 in Italian Journal of Pediatrics
Verified
Journal Article
Open access
PDF file
AIAhlam M. Ismail
Ahlam M. Ismail
AHAliaa Monir Higazi
Aliaa Monir Higazi
HNHanan Mohamed Nomeir
Hanan Mohamed Nomeir
NFNAGLAA MAKRAM FARAG
NAGLAA MAKRAM FARAG
Background: Immune thrombocytopenic purpura (ITP) is an acquired complex autoimmune thrombocytopenia. Uncontrolled cellular immune response is one of the key triggers for the loss of immune tolerance in ITP patients. The purpose of this study was to investigate the association of IL-23/Th17, IL-17A and IL-17A rs2275913 gene polymorphism with ITP in Egyptian children. Methods: 60 patients with ITP and 50 healthy control children from Minia city- Egypt were involved. Serum levels of IL-23 and IL-17A were determined by enzyme-linked immunosorbent assay. The frequency of Th17 cells was measured using flow cytometer. Genotyping for IL-17A was performed via polymerase chain reaction-restriction fragment length polymorphism. Results: Comparing children with ITP to controls, serum levels of IL-23 and IL-17A as well as Th17 cells percentage were significantly increased (p < 0.001). Also, higher levels of these ILs and Th17 cells percentage were associated with decreased platelet count within ITP patients (p < 0.001). Analysis of genotype frequencies for IL-17A rs2275913 polymorphism and its alleles (A, G) showed no significant difference between cases and controls. Likewise, no significant differences were demonstrated between acute and chronic ITP regarding both IL-17A rs2275913 polymorphism prevalence and levels of IL-23, IL-17A plus Th17 cells percentage. The frequency of A alleles was 85 and 86% within patients and controls, respectively. Conclusions: Elevated levels of IL-23, IL-17A and Th17 cells may be involved in ITP pathogenesis while IL-17A polymorphism rs2275913 is not prevalent in Egyptian children with ITP.

19 December 2022 in Vaccines
Verified
Journal Article
Open access
PDF file
MSManal Mohamed Saber
Manal Mohamed Saber
ANAzhar Mohamed Nomair
Azhar Mohamed Nomair
AOAshraf M. Osman
Ashraf M. Osman
HNHanan Mohamed Nomeir
Hanan Mohamed Nomeir
NFNAGLAA MAKRAM FARAG
NAGLAA MAKRAM FARAG
Data for predicting the severity and mortality of coronavirus disease 2019 (COVID-19) are limited, and investigations are ongoing. Endothelial monocyte-activating protein II (EMAP-II) is a multifunctional polypeptide with pro-inflammatory properties. EMAP-II is a significant pathogenic component in chronic inflammatory lung diseases and lung injury. In this study, we aimed to assess the potential utility of EMAP-II as a predictor of COVID-19 severity and mortality. This study included 20 healthy volunteers and 60 verified COVID-19 patients. Nasopharyngeal samples from COVID-19-positive subjects and normal volunteers were collected at admission. The nasopharyngeal samples were subjected to EMAP-II real-time polymerase chain reaction (RT-PCR). EMAP-II RNA was not detected in nasopharyngeal swabs of normal controls and mild to asymptomatic COVID-19 patients and was only detectable in severe COVID-19 patients. EMAP-II critical threshold (Ct) was positively associated with lymphocyte percentages and oxygen saturation (p < 0.001) while being negatively associated with age (p = 0.041), serum CRP, ferritin, and D-dimer levels (p < 0.001). EMAP-II Ct cutoff ≤34 predicted a worse outcome in COVID-19 illness, with a sensitivity and specificity of 100%. Our study suggests that EMAP-II could be considered a potential biomarker of COVID-19 severity. EMAP-II can predict the fatal outcome in COVID-19 patients.

24 January 2023 in Research Square
Verified
Preprint
Open access
PDF file
NFNAGLAA MAKRAM FARAG
NAGLAA MAKRAM FARAG
FIFaten Ismael
Faten Ismael
MMMahmoud Mousa
Mahmoud Mousa
EEEman Elsayed
Eman Elsayed
OKOmnia Kamal
Omnia Kamal
SMSamar Mansour
Samar Mansour
Background: Early identification and disease monitoring of secondary osteoporosis(OP) in rheumatoid arthritis (RA) are challenges for rheumatologists, identification of biomarkers predictive to bone mineral density (BMD) change is crucial in management. Serum 14-3-3η protein is validated as a diagnostic and prognostic biomarker in RA. Meanwhile the exact mechanism by which 14-3-3η intervenes osteoporosis is still unclear and few studies have been focused on it. Our aim was to evaluate the association among 14-3-3η protein, inflammation, bone remodeling, osteoporosis risk and disease activity in RA patients. Methods: Bone mineral density was measured using dual energy X-ray absorptiometry, serum samples were collected for all participants. Quantitative enzyme-linked immunosorbent assay (ELISA) was used to determine 14-3-3η, TNF-α and IL-6 levels. Meanwhile, B-CTX and PINP were measured using electrochemical luminescence immune-analyzer. The diagnostic value of each marker was determined via receiver operating characteristic (ROC) curve, and the association between 14-3-3η and osteoporosis was assessed using multiple logistic regression which identified 14-3-3η as an independent risk factor for RA-related osteoporosis. Results: Seventy-two RA patients and twenty five controls. Patients were divided into three subgroups, normal BMD, osteopenia, and osteoporotic. Serum 14-3-3 η, TNF-α, B-CTX and IL-6 level were the highest and PINP is the lowest in osteoporosis group, There were significant differences among the subgroups (p<0.05). Also, there were significant positive correlation between 14-3-3 η and TNF-α,B-CTX ,IL-6 (p<0.05) while it had significant negative correlation with both BMD, PINP (p<0.05). Conclusion Serum 14-3-3η is independent risk factor for RA-related osteoporosis. Serum 14-3-3η detection by itself or combined with other indices was helpful in predicting osteoporosis. Its effect on osteoporosis may be due to its role in adjusting inflammation and bone remodeling.

12 January 2023 in Research Square
Verified
Preprint
Open access
PDF file
NFNAGLAA MAKRAM FARAG
NAGLAA MAKRAM FARAG
MMMahmoud Mousa
Mahmoud Mousa
EEEman Elsayed
Eman Elsayed
AIAhlam Ismeil
Ahlam Ismeil
Background Anaemia is a common presenting feature among patients with chronic kidney disease (CKD) and associated with poor clinical outcomes. We evaluated the diagnostic validity of growth differentiation factor-15 (GDF-15) and hepcidin as it is not clear if they are useful as a biomarkers of anaemia among non-dialysis CKD egyptian patients. Method An analytical cross-sectional study was conducted among non-dialysis CKD patients (n = 60) and apparently healthy controls (n = 28) at Minia University maternity & children Hospital. Serum levels of GDF-15 and hepcidin were determined. Predictive logistic regression models were built and post estimation receiver operator characteristics were determined to evaluate diagnostic validity of hepcidin and GDF-15 for iron deficiency anaemia. Results Hepcidin and GDF-15 are significantly higher in cases than control p value (0.047,<0.0001) respectively. The predictive value of diagnosing anaemia among CKD patients using hepcidin and GDF-15 was 72.0%, 70.0%.There was a weak negative correlation between hepcidin levels and glomerular filtration rate GFR (r-175 =, p = 0.105) in CKD patients, and significant correlation between serum GDF-15 and haemoglobin (r = -0.897, p < 0.0001), ferritin (r = 0.489, P < 0.000), Iron (r=-0.314, P = 0.002), CRP (r = 0.409, P < 0.0001). Conclusion Hepcidin and GDF-15 is a potential biomarker for predicting anaemia connected with inflammation among CKD Egyptian patients.